NextEra Energy, Inc. vs Novartis AG — how do they compare? NextEra Energy, Inc. trades at $88 (market cap $183.53B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NEE | NVS | |
|---|---|---|
Market Cap | $183.53B | $290.25B |
Sector | Utilities | Health |
52-Week High | $97.88 | $168.62 |
52-Week Low | $69.77 | $113.50 |
Enterprise Value | $285.94B | $330.27B |
Dividend Yield | 2.83% | 3.17% |
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $87.93, down 0.98% with a bearish technical signal. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though Q4 2025 earnings missed expectations. Recent news highlights the proposed Dominion Energy combination and $59 billion capital expenditure plan through 2032. Analyst consensus remains strongly bullish with 66.7% buy ratings and $101.88 price target, representing 16% upside potential.
NEE offers solid long-term growth prospects from renewable energy expansion and regulatory advantages, but faces execution risks from massive capital spending and integration challenges from the Dominion merger. Current valuation at 22.34 P/E appears reasonable given growth trajectory, though technical weakness suggests near-term consolidation may continue before potential breakout.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →